O-Methylbulbocapnine and Dicentrine Suppress LPS-Induced Inflammatory Response by Blocking NF-κB and AP-1 Activation Through Inhibiting MAPKs and Akt Signaling in RAW264.7 Macrophages
Overview
Affiliations
The natural aporphine alkaloids including crebanine (CN), O-methylbulbocapnine (OMP), and dicentrine (DC), and protoberberine alkaloids, tetrahydropalmatine (THP) and N-methyl tetrahydropalmatine (NTHP), have been found in Stephania venosa. Previous reports demonstrated CN and THP exhibited anti-inflammatory properties. In this study, we investigated anti-inflammatory effect of CN analogs including OMP, DC, THP, and NTHP in RAW264.7 macrophages. The pre-treatment of macrophages with CN, OMP and DC suppressed lipopolysaccharide (LPS)-induced pro-inflammatory cytokines and mediators including interleukin-6 (IL-6), tumor necrosis factor alpha, prostaglandin E2 and nitric oxide, in which the rank-order of inhibitory potency was DC>CN≥OMP. Whereas, high dose THP (30-40 µg/mL) reduced LPS-induced IL-6 production in RAW264.7 cells but NTHP did not effect. Moreover, CN, OMP and DC inhibited the LPS-induced expression of inducible nitric oxide synthase and cyclooxygenase-2. OMP and DC inhibited LPS-induced nuclear factor kappa B (NF-κB) activation by suppressing the phosphorylation of NF-κB at Ser536, but not the nucleus translocation and inhibitor of kappaB (IκB)-α degradation. In addition, OMP and DC also reduced the phosphorylation and nucleus translocation of activator protein-1 (AP-1). Furthermore, OMP and DC suppressed the LPS-activated myeloid differentiation factor 88 (MyD88), Akt and mitogen-activated protein kinases (MAPKs) signaling pathway, which were the upstream signaling regulators of AP-1 and NF-κB. Collectively, OMP and DC have an anti-inflammatory effect on RAW264.7 macrophages by the suppression of pro-inflammatory cytokines and mediators. The inhibitory property of OMP and DC is mediated by blockage the activation of MyD88, MAPKs, Akt, NF-κB and AP-1 signaling molecules.
Dong Z, Wang X, Hu G, Huang Q, Zhang Y, Jia Y Emerg Microbes Infect. 2024; 14(1):2440490.
PMID: 39655540 PMC: 11660446. DOI: 10.1080/22221751.2024.2440490.
Liu J, Sun T, Liu S, Liu J, Fang S, Tan S Comput Biol Med. 2022; 151(Pt A):106298.
PMID: 36403355 PMC: 9671524. DOI: 10.1016/j.compbiomed.2022.106298.
Chulrik W, Jansakun C, Chaichompoo W, Tedasen A, Yotmanee P, Sattayakhom A Inflammopharmacology. 2022; 30(4):1369-1382.
PMID: 35831735 DOI: 10.1007/s10787-022-01021-y.
Xu T, Liu R, Zhu H, Zhou Y, Pei T, Yang Z Antioxidants (Basel). 2022; 11(5).
PMID: 35624778 PMC: 9137641. DOI: 10.3390/antiox11050914.
Du Q, Meng X, Wang S Front Pharmacol. 2022; 13:890078.
PMID: 35559252 PMC: 9086320. DOI: 10.3389/fphar.2022.890078.